Related Experiment Video

Updated: Nov 11, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.5K

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Elisa Agostinetto1,2, Daniel Eiger1, Kevin Punie3

  • 1Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Rue Héger-Bordet 1, 1000, Brussels, Belgium.

Current Oncology Reports
|March 25, 2021
PubMed
Abstract

Insights

Emerging treatments are improving outcomes for triple-negative breast cancer (TNBC). This review covers repurposed and novel therapies, including targeted agents and immunotherapies, offering hope for personalized patient care.

Area of Science:

  • Oncology
  • Medical Therapeutics

Background:

  • Triple-negative breast cancer (TNBC) represents 10-15% of all breast cancers.
  • TNBC is historically associated with a poorer prognosis compared to other subtypes.
  • Recent therapeutic advancements are beginning to improve outcomes for TNBC patients.

Purpose of the Study:

  • To provide a comprehensive overview of emerging therapeutic strategies for TNBC.
  • To discuss both repurposed approved therapies and novel targeted treatments.
  • To highlight advancements that may enhance patient outcomes in TNBC.

Main Methods:

  • Review of current and emerging treatment modalities for TNBC.
  • Analysis of clinical investigations into novel drug combinations and targeted therapies.
  • Synthesis of data on approved therapies being repurposed for TNBC treatment.

Main Results:

  • New therapeutic strategies are significantly impacting the TNBC treatment landscape.
  • Approved therapies are being repurposed, alongside novel agents like PARP inhibitors and immune checkpoint inhibitors.
  • Combination therapies targeting pathways such as AKT/PI3K/mTOR, and agents like CDK-inhibitors and antibody-drug conjugates are under investigation.
  • The evolving TNBC treatment landscape is moving towards personalized medicine.

Conclusions:

  • The treatment of triple-negative breast cancer is rapidly advancing with new therapeutic options.
  • Emerging therapies, including targeted agents and immunotherapies, hold significant promise for improving patient outcomes.
  • A personalized approach to TNBC treatment is becoming increasingly feasible and expected.
Keywords:
Breast cancer,ImmunotherapyNew therapies,New treatments,PARP inhibitors,Triple-negative breast cancer,

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.3K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
820
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K